Literature DB >> 11118121

Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.

J D Moore1, G Valette, A Darque, X J Zhou, J P Sommadossi.   

Abstract

A high-performance liquid chromatography (HPLC) method utilizing triple quadrupole mass spectrometry (MS) detection was developed and validated for the simultaneous measurement of the intracellular nucleoside 5'-triphosphate anabolites of zidovudine (ZDV-TP), lamivudine (3TC-TP), and stavudine (d4T-TP). These compounds were extracted from patient peripheral blood mononuclear cells (PBMCs) which are the sites of HIV replication and drug action. Ion-exchange solid phase extraction (SPE) followed by enzymatic digestion with alkaline phosphatase was utilized to yield the measurable nucleoside forms of the nucleotides. Reversed phase C-18 SPE with addition of a nucleoside internal standard, 3'-azido-2',3'-dideoxyuridine (AzdU) allowed for the indirect measurement of the original 5'-triphosphate concentration by HPLC/MS/MS. Quantitation was performed from calibration curves generated from authentic 5'-triphosphate standards spiked in PBMCs from healthy volunteers. Analytical range for the three 5'-triphosphates was equivalent to 50-45,000 pg. Mean interassay accuracies for 3TC-TP, d4T-TP, and ZDV-TP (n > 90) were 99.4%, 100.1%, and 108.0%, respectively. Mean interassay precisions (%C.V.) for 3TC-TP, d4T-TP, and ZDV-TP (n > 90) were 8.8%, 10.4%, and 8.2%, respectively. Recovery of the extraction method was 79.2%, 83.1%, and 98.3% for 3TC-TP, d4T-TP, and ZDV-TP, respectively. This method can be utilized to measure the intracellular 5'-triphosphate levels in HIV infected patients receiving antiretroviral therapy containing the nucleoside reverse transcriptase inhibitors 3TC, d4T, or ZDV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118121     DOI: 10.1016/S1044-0305(00)00178-1

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  20 in total

1.  Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.

Authors:  R Gulick
Journal:  AIDS       Date:  1998       Impact factor: 4.177

2.  A sensitive nonisotopic method for the determination of intracellular azidothymidine 5'-mono-, 5'-di-, and 5'-triphosphate.

Authors:  T Toyoshima; S Kimura; S Muramatsu; H Takahagi; K Shimada
Journal:  Anal Biochem       Date:  1991-08-01       Impact factor: 3.365

3.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Authors:  N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

4.  Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.

Authors:  B L Robbins; B H Waibel; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Lamivudine (3TC) phosphorylation and drug interactions in vitro.

Authors:  S Kewn; G J Veal; P G Hoggard; M G Barry; D J Back
Journal:  Biochem Pharmacol       Date:  1997-09-01       Impact factor: 5.858

6.  Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.

Authors:  C Solas; Y F Li; M Y Xie; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus.

Authors:  K Peter; J G Gambertoglio
Journal:  Clin Pharmacol Ther       Date:  1996-08       Impact factor: 6.875

8.  Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides.

Authors:  W Y Gao; D G Johns; H Mitsuya
Journal:  Anal Biochem       Date:  1994-10       Impact factor: 3.365

9.  Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure.

Authors:  J T Slusher; S K Kuwahara; F M Hamzeh; L D Lewis; D M Kornhauser; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients.

Authors:  B L Robbins; T T Tran; F H Pinkerton; F Akeb; R Guedj; J Grassi; D Lancaster; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  10 in total

Review 1.  Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples.

Authors:  Nagsen Gautam; Jawaher Abdullah Alamoudi; Sushil Kumar; Yazen Alnouti
Journal:  J Pharm Biomed Anal       Date:  2019-10-03       Impact factor: 3.935

2.  Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

Authors:  Stephen Kewn; Patrick G Hoggard; Sean D Sales; Kevin Jones; Bridget Maher; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.

Authors:  M Rodriguez-Torres; F J Torriani; V Soriano; M J Borucki; E Lissen; M Sulkowski; D Dieterich; K Wang; J-M Gries; P G Hoggard; D Back
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

Authors:  J Gerardo García-Lerma; Hamish MacInnes; Diane Bennett; Patrick Reid; Soumya Nidtha; Hillard Weinstock; Jonathan E Kaplan; Walid Heneine
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 5.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells.

Authors:  Margarita Meléndez; Osvaldo Rosario; Beatriz Zayas; José F Rodríguez
Journal:  J Pharm Biomed Anal       Date:  2009-02-13       Impact factor: 3.935

7.  Lack of evidence for in vivo transformation of zidovudine triphosphate to stavudine triphosphate in human immunodeficiency virus-infected patients.

Authors:  Margarita Meléndez; Raúl Blanco; Wilfredo Delgado; Rosario García; Jorge Santana; Hermes García; Osvaldo Rosario; José F Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.

Authors:  Stephen Kewn; Laurene H Wang; Patrick G Hoggard; Franck Rousseau; Robert Hart; John P MacNeela; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.

Authors:  Cecile Le Saint; Raphael Terreux; Daniele Duval; Jacques Durant; Helene Ettesse; Pierre Dellamonica; Roger Guedj; Jean Pierre Vincent; Anny Cupo
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.

Authors:  Geoffrey J Yuen; Yu Lou; Nancy F Bumgarner; Jim P Bishop; Glenn A Smith; Victoria R Otto; David D Hoelscher
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.